In the ToGA study, combination therapy of the anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with 5-fluorouracil or capecitabine plus cisplatin showed significantly improved survival compared with CT alone in patients with HER2-positive late-stage gastric cancer [5]. This evidence concerns the gene ERBB2 and gastric cancer.